[New immunoglobulin for treatment of anthrax].

AIM: To experimentally assess activity and safety of anti-anthrax intravenous immunoglobulin manufactured on standard technology. MATERIALS AND METHODS: Plasma from selected donors vaccinated with combined anthrax vaccine was tested by enzyme immunoassay. Samples of plasma with increased titer of anti-anthrax antibodies were merged in one manufacturing load and fractionated in ethanol at negative temperature according to standard technology. Formulation of intravenous immunoglobulin was manufactured according to standard technology of acid-enzyme hydrolysis. RESULTS: Proved medical technology of donors immune plasma fractionation provided 4 - 8-fold concentration of anti-anthrax antibodies. The finished product contained 5% of protein and was apyrogenic, non-toxic, thermostable, electrophoretically homogenous, had pH 6.65 and meet the requirements for manufacturing batches of human intravenous immunoglobulin. CONCLUSION: Protective effects of experimental human anti-anthrax immunoglobulin were comparable with control biological--equine anti-anthrax immunoglobulin for intramuscular use.

[Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route]. / Nekotorye patogeneticheskie kharakteristiki zabolevaniia obez'ian, aérogenno infitsirovannykh virusom Marburg.

Time course of Marburg virus (strain Popp) accumulation and changes in hematological parameters were studied in aerosol infected M.rhesus monkeys. The lungs were the first organ in which the virus was detected after respiratory infection of monkeys. Four days after inoculation the virus was detected in the liver, spleen, blood, and thymus. Six days after inoculation the virus was present in virtually all organs and secretions. The period of fever was associated with manifest leukopenia in primates. Blood clotting time drastically increased by the moment of animal death.

[The efficacy of the emergency prophylactic and therapeutic actions of immunomodulators in experimental filovirus infections]. / Effektivnost' ékstrenno-profilakticheskogo i lechebnogo deistviia immunomoduliatorov pri éksperimental'nykh filovirusnykh infektsiiakh.

The study of the preventive and therapeutic action of some immunomodulators (ridostin, reaferon and polyribonate) used alone and in combinations was conducted on laboratory animals infected aerogenically by Marburg or Ebola virus. It was found that special preventive intranasal and intramuscular administration of ridostin provided protection of the animals infected by Marburg virus (p = 0.1) and an increase in their mean lifespan by 2.4 days (p = 0.15). In the Ebola infection combined administration of ridostin and reaferon caused an essential increase in the mean lifespan of the animals by 2.9 days (p = 0.04). None of the tested drugs had any significant positive effect when used in various combinations according to the treatment schemes in Marburg and Ebola infections in guinea pigs.

[Clinical-virusological characteristics of disease in guinea pigs, infected by the Marburg virus aerogenically]. / Kliniko-virusologicheskie kharakteristiki zabolevaniia morskikh svinok, aerogenno infitsirovannykh virusom Marburg.

Marburg virus (strain Popp) was found to accumulate in various organs of guinea pigs after aerogenic infection. At the initial stage of the infection primary multiplication of the virus took place in the lungs. The presence of the virus in bronchopulmonary washings 2-3 days after infection, leukopenia and hyperthermia 4 days after infection are the earliest virological and clinical signs of disease in aerogenically infected guinea pigs.